A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.
Clinical trial NCT00708292 · COMPLETED
Trial details
- NCT number
- NCT00708292
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2008-07-01
- Primary completion
- 2011-01-01
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.